Press Release: Novartis Kesimpta(R) six-year -2-

At Novartis, in Neuroscience, we are committed to understanding and solving some of the most burdensome neurological conditions to improve the quality of life for patients and their caregivers, and to make a positive impact on society. We aim to lead the discovery, development and delivery of innovative medicines to create a transformational impact for people living with severe neurological conditions by changing the course of disease progression.

Through innovation, partnerships and community engagement, we have been tackling neurological conditions for >80 years, launching transformative treatments which have made meaningful differences to millions of people worldwide. We continue to collaborate on the development of industry-leading innovative medicines for multiple sclerosis, and in the areas of neuroimmunology, neurodegeneration, and neuromuscular/rare diseases.

To ensure patients everywhere can benefit from these life-changing therapies, we work closely with key stakeholders across the world to ensure rapid access and sustainable accessibility to our medicines, with the aim of providing the best treatment choices for each person's unique journey.

Disclaimer

This is a legal statement identifying forward-looking statements involving known and unknown risks and uncertainties. You should include the standard disclaimer in your release as outlined in the Global Press Release Approval Guidelines.

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Pardo G, Hauser SL, Bar-Or A, et al. Longer-term (up to 6 Years) Efficacy

of Ofatumumab in People with Recently Diagnosed and Treatment-Naïve

Relapsing Multiple Sclerosis. Oral presentation at the American Academy

of Neurology (AAN) 2024 Annual Meeting; April 13-18, 2024; Denver, CO.

2. Wiendl H, Hauser SL, Nicholas J, et al. Longer-term Safety and Efficacy

of Ofatumumab in People With Relapsing Multiple Sclerosis for Up to 6

Years. Poster presentation at the American Academy of Neurology (AAN)

2024 Annual Meeting; April 13-18, 2024; Denver, CO.

3. Guthrie EW. Multiple sclerosis: A primer and update. Adv Studies Pharm.

2007;4(11):313-317.

4. Multiple Sclerosis International Federation. Atlas of MS 2013-Mapping

Multiple Sclerosis Around the World. Accessed August 12, 2020.

http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf

5. National MS Society. Types of MS. Accessed January 18, 2023.

https://www.nationalmssociety.org/What-is-MS/Types-of-MS

6. Hauser SL, Kappos L, Bar-Or A, et al. The Development of Ofatumumab, a

Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing

Multiple Sclerosis Treatment. Neurol Ther. 2023;12(5):1491-1515.

doi:10.1007/s40120-023-00518-0

7. Kesimpta Prescribing Information. East Hanover, NJ: Novartis

Pharmaceuticals Corp; September 2022.

8. Bar-Or A, Fox E, Goodyear A, et al. Onset of B-cell depletion with

subcutaneous administration of ofatumumab in relapsing multiple

sclerosis: results from the APLIOS bioequivalence study. Poster

presentation at: ACTRIMS; February 2020; West Palm Beach, FL.

9. Smith P, Kakarieka A, Wallstroem E. Ofatumumab is a fully human anti-CD20

antibody achieving potent B-cell depletion through binding a distinct

epitope. Poster presentation at: ECTRIMS; September 2016; London, UK.

10. Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20

therapy effectively depletes B-cells and ameliorates CNS autoimmunity.

Poster presentation at: ECTRIMS; September 2016; London, UK.

11. Cohen, JA, Hauser SL, Zielman R., et al. Effect of Longer-term Ofatumumab

Treatment on Disability Progression and Brain Volume Change. Poster

presentation at: AAN; April 2023; Boston, US.

12. Genmab Press Release: Genmab announces completion of agreement to

transfer remaining ofatumumab rights. December 21, 2015. Accessed January

18, 2023.

https://ir.genmab.com/static-files/9d491b72-bb0b-4e46-a792-dee6c29aaf7d

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Richard Jarvis +41 79 584 2326 Michael Meo +1 862 274 5414

Anja von Treskow +41 79 392 9697 Marlena Abdinoor +1 617 335 9525

Anna Schäfers +41 79 801 7267

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

April 17, 2024 01:15 ET (05:15 GMT)